Loading
Crizotinib shrank tumours in almost three quarters of patients with ROS1-rearranged lung cancer and controlled the disease for a median of 19 months, establishing ROS1 as a targetable driver and leading to the first approval.
Expansion cohort of a phase 1 study treating 50 patients with advanced ROS1-rearranged non-small-cell lung cancer with crizotinib 250 mg twice daily.
Objective response was 72 percent with median duration of response 17.6 months and median progression-free survival 19.2 months; the safety profile matched that seen in ALK-positive disease.
ROS1 testing became standard in lung adenocarcinoma; crizotinib was the first approved ROS1 inhibitor and remains an option, though entrectinib, repotrectinib and taletrectinib now offer brain penetration and resistance coverage.
Shares ROS1-positive non-small-cell lung cancer, Crizotinib.
Shares ROS1-positive non-small-cell lung cancer, Crizotinib.
Shares Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer, New England Journal of Medicine.
Shares ROS1-positive non-small-cell lung cancer, Crizotinib.
Shares Alice T. Shaw, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer, Crizotinib, New England Journal of Medicine.
Shares Alice T. Shaw, Crizotinib, New England Journal of Medicine.
Shares ROS1-positive non-small-cell lung cancer, New England Journal of Medicine.